U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07055282) titled 'SGLT2i in Kidney Stones' on June 24.
Brief Summary: This study is looking at whether empagliflozin, a medication typically used for diabetes and heart conditions, may affect factors that contribute to kidney stone formation. The research focuses on people who have had calcium-based kidney stones, i.e. calcium oxalate or calcium phosphate stones.
Previous studies in those without kidney stones found that empagliflozin increased urinary citrate levels without raising urine pH. The investigators are testing whether similar effects occur in people with a history of kidney stones.
Participants will take empagliflozin daily for 4 weeks. ...